The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and Is BPC 157 Banned? Oral vs. Injectable Forms Explained FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with